BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother. 2002;51:219-228. [PMID: 12012109 DOI: 10.1007/s00262-002-0273-7] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Xu B, Chen F, Zhang X, Wang Z, Che K, Wu N, Yu L, Fan X, Liu B, Wei J. Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers 2022;14:2758. [DOI: 10.3390/cancers14112758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu T, Tan J, Wu M, Fan W, Wei J, Zhu B, Guo J, Wang S, Zhou P, Zhang H, Shi L, Li J. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells. Gut 2021;70:1965-77. [PMID: 33262196 DOI: 10.1136/gutjnl-2020-322196] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
3 Zhang W, Yin Q, Huang H, Lu J, Qin H, Chen S, Zhang W, Su X, Sun W, Dong Y, Li Q. Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021;11:628456. [PMID: 33928024 DOI: 10.3389/fonc.2021.628456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
4 Donnelly CG, Bellone RR, Hales EN, Nguyen A, Katzman SA, Dujovne GA, Knickelbein KE, Avila F, Kalbfleisch TS, Giulotto E, Kingsley NB, Tanaka J, Esdaile E, Peng S, Dahlgren A, Fuller A, Mienaltowski MJ, Raudsepp T, Affolter VK, Petersen JL, Finno CJ. Generation of a Biobank From Two Adult Thoroughbred Stallions for the Functional Annotation of Animal Genomes Initiative. Front Genet 2021;12:650305. [PMID: 33763124 DOI: 10.3389/fgene.2021.650305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y, Liu Q, Wang Q, Sun Z, Zhou S, Du S, Wei J, Liu B. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest 2019;129:2056-70. [PMID: 30835255 DOI: 10.1172/JCI99538] [Cited by in Crossref: 87] [Cited by in F6Publishing: 96] [Article Influence: 21.8] [Reference Citation Analysis]
6 Burns EN, Bordbari MH, Mienaltowski MJ, Affolter VK, Barro MV, Gianino F, Gianino G, Giulotto E, Kalbfleisch TS, Katzman SA, Lassaline M, Leeb T, Mack M, Müller EJ, MacLeod JN, Ming-Whitfield B, Alanis CR, Raudsepp T, Scott E, Vig S, Zhou H, Petersen JL, Bellone RR, Finno CJ. Generation of an equine biobank to be used for Functional Annotation of Animal Genomes project. Anim Genet 2018;49:564-70. [PMID: 30311254 DOI: 10.1111/age.12717] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
7 Taborska P, Stakheev D, Strizova Z, Vavrova K, Podrazil M, Bartunkova J, Smrz D. Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients. Med Oncol 2017;34. [DOI: 10.1007/s12032-017-1035-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
8 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
9 Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. Int Immunopharmacol 2017;44:197-202. [PMID: 28110220 DOI: 10.1016/j.intimp.2017.01.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yutani S, Itoh K. Personalized Peptide Vaccine for Advanced Pancreatic Cancer. Pancreatic Cancer 2017. [DOI: 10.1007/978-3-662-47181-4_40] [Reference Citation Analysis]
11 Krishna S, Anderson KS. T-Cell Epitope Discovery for Therapeutic Cancer Vaccines. In: Thomas S, editor. Vaccine Design. New York: Springer; 2016. pp. 779-96. [DOI: 10.1007/978-1-4939-3387-7_45] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
12 Sakamoto S, Noguchi M, Yamada A, Itoh K, Sasada T. Prospect and progress of personalized peptide vaccinations for advanced cancers. Expert Opin Biol Ther 2016;16:689-98. [PMID: 26938083 DOI: 10.1517/14712598.2016.1161752] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
13 Matsueda S, Shichijo S, Nagata S, Seki C, Yamada A, Noguchi M, Itoh K. Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine. Cancer Sci 2015;106:1493-8. [PMID: 26331453 DOI: 10.1111/cas.12805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
14 Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco MA, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles. Int Immunopharmacol 2015;26:133-8. [PMID: 25819666 DOI: 10.1016/j.intimp.2015.03.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma. Int Immunopharmacol 2014;20:59-65. [PMID: 24583149 DOI: 10.1016/j.intimp.2014.02.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
16 Takao Y, Yamada A, Yutani S, Sata M, Itoh K. Antibody Reactive to a Hepatitis C Virus (HCV)-Derived Peptide Capable of Inducing HLA-A2 Restricted Cytotoxic T Lymphocytes Is Detectable in a Majority of HCV-Infected Individuals without HLA-A2 Restriction. Microbiology and Immunology 2004;48:507-17. [DOI: 10.1111/j.1348-0421.2004.tb03546.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yoshimura K, Minami T, Nozawa M, Uemura H. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br J Cancer 2013;108:1260-6. [PMID: 23470466 DOI: 10.1038/bjc.2013.90] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
18 Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother. 2013;62:919-929. [PMID: 23197273 DOI: 10.1007/s00262-012-1379-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
19 Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 2012;120:1613-23. [PMID: 22645177 DOI: 10.1182/blood-2011-09-382838] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
20 Tanaka E, Sato T, Ishihara M, Tsutsumi Y, Hisano M, Chikamoto H, Akioka Y, Dohno S, Maeda A, Hattori M. Asymptomatic high Epstein-Barr viral load carriage in pediatric renal transplant recipients. Pediatr Transplant. 2011;15:306-313. [PMID: 21492352 DOI: 10.1111/j.1399-3046.2010.01465.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
21 Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 2011;17:5945-52. [PMID: 21813633 DOI: 10.1158/1078-0432.CCR-11-0970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
22 Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int 2011;108:831-8. [PMID: 21166757 DOI: 10.1111/j.1464-410X.2010.09933.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
23 Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, Itoh K. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011;29:337-44. [PMID: 21149665 DOI: 10.1200/JCO.2010.29.7499] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 6.5] [Reference Citation Analysis]
24 Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K. Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Exp Ther Med 2011;2:109-17. [PMID: 22977478 DOI: 10.3892/etm.2010.177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
25 Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer: Peptide Vaccination for Prostate Cancer. Prostate 2011;71:470-9. [DOI: 10.1002/pros.21261] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
26 Aggarwal R, Harzstark A. Research Highlights. Personalized Medicine 2010;7:479-83. [DOI: 10.2217/pme.10.54] [Reference Citation Analysis]
27 Komatsu N, Terasaki Y, Moriya F, Suekane S, Noguchi M, Todo S, Itoh K, Shichijo S. A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients. Exp Ther Med 2010;1:833-9. [PMID: 22993607 DOI: 10.3892/etm.2010.120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer. 2010;46:1514-1519. [PMID: 20413296 DOI: 10.1016/j.ejca.2010.03.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
29 Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010;59:1001-9. [DOI: 10.1007/s00262-010-0822-4] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
30 Weng J, Neelapu SS, Woo AF, Kwak LW. Identification of human idiotype-specific T cells in lymphoma and myeloma. Curr Top Microbiol Immunol 2011;344:193-210. [PMID: 20549471 DOI: 10.1007/82_2010_70] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
31 Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti‐peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scandinavian Journal of Clinical and Laboratory Investigation 2009;64:535-46. [DOI: 10.1080/00365510410007008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
32 Hattori T, Mine T, Komatsu N, Yamada A, Itoh K, Shiozaki H, Okuno K. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother. 2009;58:1843-1852. [PMID: 19396597 DOI: 10.1007/s00262-009-0695-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
33 Terasaki Y, Shichijo S, Niu Y, Komatsu N, Noguchi M, Todo S, Itoh K. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother 2009;58:1877-85. [PMID: 19330328 DOI: 10.1007/s00262-009-0699-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
34 Jin M, Komohara Y, Shichijo S, Yamanaka R, Nikawa J, Itoh K, Yamada A. Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci 2008;99:1656-62. [PMID: 18754880 DOI: 10.1111/j.1349-7006.2008.00866.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
35 Iwamoto O, Koga M, Aoki M, Yokomizo Y, Koga C, Kusukawa J, Sasatomi T, Itoh K. Aberrant Expression of p56lck in Primary Oral Cancer. Asian Journal of Oral and Maxillofacial Surgery 2007;19:190-196. [DOI: 10.1016/s0915-6992(07)80002-1] [Reference Citation Analysis]
36 Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada A, Itoh K, Harada M. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer 2007;97:1648-54. [PMID: 18043580 DOI: 10.1038/sj.bjc.6604071] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
37 Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007;30:274-81. [PMID: 17414318 DOI: 10.1097/01.cji.0000211340.88835.e7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
38 Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishihara Y, Yamada A. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci. 2007;98:1113-1119. [PMID: 17459063 DOI: 10.1111/j.1349-7006.2007.00498.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
39 Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, Itoh K, Matsuoka K. Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma. Journal of Urology 2007;177:1157-62. [DOI: 10.1016/j.juro.2006.10.035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
40 Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, Takahashi K, Nakahara K, Honma S, Tanaka M, Mizoguchi J, Yamada A, Oka M, Kamiyama Y, Itoh K, Takai S. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 2007;98:605-11. [PMID: 17309598 DOI: 10.1111/j.1349-7006.2007.00429.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
41 Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci. 2006;97:970-976. [PMID: 16984371 DOI: 10.1111/j.1349-7006.2006.00272.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 4.1] [Reference Citation Analysis]
42 Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother. 2007;56:689-698. [PMID: 16937115 DOI: 10.1007/s00262-006-0216-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
43 Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate 2004;60:273-81. [DOI: 10.1002/pros.20078] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
44 Yao A, Harada M, Matsueda S, Ishihara Y, Shomura H, Noguchi M, Matsuoka K, Hara I, Kamidono S, Itoh K. Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients. Br J Cancer 2004;91:287-96. [PMID: 15199397 DOI: 10.1038/sj.bjc.6601960] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
45 Shomura H, Shichijo S, Komatsu N, Matsueda S, Mine T, Rikimaru T, Sato Y, Todo S, Itoh K. Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients. European Journal of Cancer 2004;40:1776-86. [DOI: 10.1016/j.ejca.2004.04.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
46 Yao A, Harada M, Matsueda S, Ishihara Y, Shomura H, Takao Y, Noguchi M, Matsuoka K, Hara I, Kamidono S, Itoh K. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2 + prostate cancer patients: HLA-A2 Binding Peptides of PTHrP. Prostate 2005;62:233-42. [DOI: 10.1002/pros.20133] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
47 Sato Y, Maeda Y, Shomura H, Sasatomi T, Takahashi M, Une Y, Kondo M, Shinohara T, Hida N, Katagiri K. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer. 2004;90:1334-1342. [PMID: 15054451 DOI: 10.1038/sj.bjc.6601711] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
48 Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004;60:32-45. [DOI: 10.1002/pros.20011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
49 Harada M, Gohara R, Matsueda S, Muto A, Oda T, Iwamoto Y, Itoh K. In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide. J Immunol 2004;172:2659-67. [PMID: 14764741 DOI: 10.4049/jimmunol.172.4.2659] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
50 Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K, Tamura M, Yamada A, Morinaga A, Nishikori M, Katagiri K, Itoh K, Yamana H, Hashimoto T. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother 2003;26:357-66. [PMID: 12843798 DOI: 10.1097/00002371-200307000-00008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
51 Sato Y, Shomura H, Maeda Y, Mine T, Une Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 2003;94:802-808. [PMID: 12967479 DOI: 10.1111/j.1349-7006.2003.tb01522.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 2.8] [Reference Citation Analysis]
52 Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H. Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses. Clinical Cancer Research 2004;10:929-937. [DOI: 10.1158/1078-0432.ccr-1117-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 4.6] [Reference Citation Analysis]
53 Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K, Kamura T. Vaccination with Predesignated or Evidence-Based Peptides for Patients with Recurrent Gynecologic Cancers: . Journal of Immunotherapy 2004;27:60-72. [DOI: 10.1097/00002371-200401000-00006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 2.7] [Reference Citation Analysis]
54 Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, Harada M. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24? prostate cancer patients. Prostate 2004;60:205-13. [DOI: 10.1002/pros.20038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
55 Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H, Noda S. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Science 2004;95:77-84. [DOI: 10.1111/j.1349-7006.2004.tb03174.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
56 Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003;57:80-92. [PMID: 12886526 DOI: 10.1002/pros.10276] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
57 Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate 2003;57:152-9. [DOI: 10.1002/pros.10280] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
58 Kobayashi K, Noguchi M, Itoh K, Harada M. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Science 2003;94:622-7. [DOI: 10.1111/j.1349-7006.2003.tb01493.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
59 Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirouzu K, Itoh K, Yamana H. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Science 2003;94:548-56. [DOI: 10.1111/j.1349-7006.2003.tb01481.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 2.2] [Reference Citation Analysis]
60 Yamaguchi Y, Kawabuchi Y, Ohshita A, Toge T. Screening of CEA Epitope Peptide using the Whole Blood Assay. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2003;36:171-171. [DOI: 10.5833/jjgs.36.171] [Reference Citation Analysis]
61 Maeda Y, Hida N, Niiya F, Katagiri K, Harada M, Yamana H, Kamura T, Takahashi M, Sato Y, Todo S, Itoh K. Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients. Br J Cancer 2002;87:796-804. [PMID: 12232766 DOI: 10.1038/sj.bjc.6600548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]